Aytu BioPharma (AYTU) announced that the method of use patent for EXXUA extended-release tablets has been extended through September 2, 2030 under 35 U.S.C. 156. The patent extension further expands upon the new chemical entity exclusivity period granted by the United States Food and Drug Administration. Gepirone is an NCE, and EXXUA is the first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for the treatment of major depressive disorder in adults.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AYTU:
- Aytu BioPharma management to meet with Lake Street
- Aytu BioPharma price target lowered to $7 from $9 at Maxim
- Aytu BioPharma’s Optimistic Earnings Call Highlights ExuA Launch
- Aytu BioPharma Reports Fiscal 2025 Earnings and EXXUA Launch Plans
- AYTU Earnings Report this Week: Is It a Buy, Ahead of Earnings?